• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Cook Jason claimed ownership of 49,900 shares

    3/16/23 12:56:10 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care
    Get the next $BJDX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Cook Jason

    (Last) (First) (Middle)
    C/O BLUEJAY DIAGNOSTICS, INC.
    360 MASSACHUSETTS AVE, SUITE 203

    (Street)
    ACTON MA 01720

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/07/2023
    3. Issuer Name and Ticker or Trading Symbol
    Bluejay Diagnostics, Inc. [ BJDX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Technology Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 5,000 D
    Common Stock 44,900 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Options to purchase common stock (1) 07/07/2031 Common Stock 75,000 3.5 D
    Options to purchase common stock (2) 02/25/2032 Common Stock 5,324 1.09 D
    Explanation of Responses:
    1. The stock options vest as follows: a) 41,668 immediately upon grant, and b) 8,333 each upon attainment of four different performance conditions
    2. The stock options vest in three equal installments on the first, second and third anniversaries of the grant date.
    /s/ Jason Cook 03/16/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BJDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BJDX

    DatePrice TargetRatingAnalyst
    1/12/2022$10.00Buy
    Dawson James
    More analyst ratings

    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

    ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, the Company now has approximately 972,000 shares of common stock outstanding. In addition, the Company has cash exercisable warrants outstanding for approximately 1.5 million shares. All such warrants have a cash exercise price of $7.00 or greater per share. The Company notes that several recent Schedule 13G filings made by investors

    2/20/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

    ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initiatives into 2026, representing a key execution milestone as the Company transitions from clinical enrollment toward data analysis, regulatory engagement, and commercialization readiness. SYMON-II Clinical trialsBluejay is successfully enrolling across all participating sites in its SYMON™ II multicenter IL-6 monitoring study, with a total of 545 patients enrolled with a target of 750 patients, exceeding i

    2/17/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

    ACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-4 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on January 29, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on January 29, 2026 under the Company's existing trading symbol, "BJDX." A

    1/27/26 8:00:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

    4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

    12/14/23 4:17:42 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

    4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

    12/14/23 4:16:33 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $BJDX
    SEC Filings

    View All

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    2/20/26 9:54:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Bluejay Diagnostics Inc.

    SCHEDULE 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    2/18/26 4:48:34 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    2/17/26 9:54:58 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

    4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

    12/14/23 4:17:42 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

    4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

    12/14/23 4:16:33 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Scally Frances P

    3 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

    10/11/23 7:21:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dawson James initiated coverage on Bluejay Diagnostics with a new price target

    Dawson James initiated coverage of Bluejay Diagnostics with a rating of Buy and set a new price target of $10.00

    1/12/22 9:00:51 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $BJDX
    Leadership Updates

    Live Leadership Updates

    View All

    Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

    ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company") a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin "Ed" E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report to Neil Dey, Chief Executive Officer. Mr. Rule is a highly credentialed regulatory, quality and compliance professional with more than 15 years of industry experience. He has extensive training and expertise in medical device regulations in the U.S. and numerous international markets.

    3/28/22 7:00:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

    ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay") a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay's clinical development programs and provide strategic medical and scientific leadership to the Company. "I am very pleased to welcome Mark on board as Chief Medical Advisor. I believe Mark's expansive clinical background and strategic leadership skills will be invaluable as we seek to develop the Compa

    1/5/22 8:15:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

    SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 3:54:54 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    7/3/24 4:01:01 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care